Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Federico, Campigotto"'
Autor:
Becky Yang, Ping Yi, Jens Brodbeck, Shiva Zaboli, Federico Campigotto, Marianna Zavodovskaya, Susanna Stinson, Jianhua He, Kyung-Hoon Kim, Monika Sobczyk, Rutwij Dave, Brian Carr, In Kyoung Mah, Scott Turner, Vivian Barry, Kelli Boyd, Valeria Fantin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/2573e5a7d8674f8f97980eab63bf8eab
Autor:
Maria Fleseriu, Chioma Iweha, Luiz Salgado, Tania Longo Mazzuco, Federico Campigotto, Ricardo Maamari, Padiporn Limumpornpetch
Publikováno v:
Frontiers in Endocrinology, Vol 10 (2019)
Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's dise
Externí odkaz:
https://doaj.org/article/398a249f1b47463494ec5336156e3976
Autor:
David Avigan, Donald Kufe, Kenneth Anderson, Jacob Rowe, Viki Held, Lina Bisharat, Yan Emily Yuan, Vassiliki Boussiotis, Noopur Raje, Jacob Laubach, Paul Richardson, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Edie Weller, Federico Campigotto, Heidi Mills, Poorvi Somaiya, Bimalangshu R. Dey, Tami Katz, Nikhil C. Munshi, Lynne Uhl, Baldev Vasir, Irit Avivi, Jacalyn Rosenblatt
Purpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008e112b659829c9a6b5df166a140425
https://doi.org/10.1158/1078-0432.c.6522116
https://doi.org/10.1158/1078-0432.c.6522116
Autor:
David Avigan, Donald Kufe, Kenneth Anderson, Jacob Rowe, Viki Held, Lina Bisharat, Yan Emily Yuan, Vassiliki Boussiotis, Noopur Raje, Jacob Laubach, Paul Richardson, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Edie Weller, Federico Campigotto, Heidi Mills, Poorvi Somaiya, Bimalangshu R. Dey, Tami Katz, Nikhil C. Munshi, Lynne Uhl, Baldev Vasir, Irit Avivi, Jacalyn Rosenblatt
PDF file - 522K, Percentage of CD8+T cells recognizing MUC1 tetramer in HLA 2.1+ patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bf3b43e4e929fad1e7ca4d48bfe971
https://doi.org/10.1158/1078-0432.22451159.v1
https://doi.org/10.1158/1078-0432.22451159.v1
Autor:
Samuel J. Vidal, Elena Bekerman, Derek Hansen, Bing Lu, Kelly Wang, Judy Mwangi, William Rowe, Federico Campigotto, Jim Zheng, Darryl Kato, Abishek Chandrashekar, Julia Barrett, Shivani Patel, Huahua Wan, Tochi Anioke, Noe B. Mercado, Joseph P. Nkolola, Melissa J. Ferguson, William J. Rinaldi, Christian Callebaut, Wade Blair, Tomas Cihlar, Romas Geleziunas, Stephen R. Yant, Dan H. Barouch
Publikováno v:
Nature
Because no currently available vaccine can prevent HIV infection, pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) is an important tool for combating the HIV pandemic1,2. Long-acting ARVs promise to build on the success of current PrEP str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18528a97089342386940b1681f96dfdc
http://europepmc.org/articles/PMC8753592
http://europepmc.org/articles/PMC8753592
Autor:
Julie A Di Paolo, Amy Meng, Bernard Murray, Paqui G. Través, Federico Campigotto, René Galien
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveJanus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3e2584ca5fa719702f7eec30d7c281
http://europepmc.org/articles/PMC8237188
http://europepmc.org/articles/PMC8237188
Autor:
Georgina V. Long, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaëlle Quéreux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, John M. Kirkwood
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s163
Patients with resected stage IIB/C melanoma are at high risk of recurrence with outcomes similar to patients with resected stage IIIB disease. Adjuvant NIVO has shown benefit in patients with resected stage III-IV melanoma. The phase 3 CheckMate 76K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d9b727cb40f7439758d3be3df85999d
https://doi.org/10.25251/skin.7.supp.163
https://doi.org/10.25251/skin.7.supp.163
Publikováno v:
Journal of Clinical Oncology. 40:1597-1598
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df0d6d90663d60a0e74311a553ce2a41
https://doi.org/10.1200/jco.22.00209
https://doi.org/10.1200/jco.22.00209
Autor:
Wally R. Smith, Christina Wiedl, Joseph Rosenthal, Laura M. De Castro, Marcus Spearman, Keith M. Sullivan, Kathryn L. Hassell, Nitya Bakshi, Edmund K. Waller, Naynesh Kamani, Wandi Zhang, Catherine J. Wu, Kristen E. Stevenson, Shannon L. Smith, Donna Neuberg, Suhag Parikh, Mark C. Walters, Rebekah K. Loving, Allistair Abraham, Ann E. Haight, Federico Campigotto, Lakshmanan Krishnamurti, Thabat Dahdoul
Publikováno v:
American journal of hematology, vol 94, iss 4
We conducted a multicenter pilot investigation of the safety and feasibility of bone marrow transplantation (BMT) in adults with severe sickle cell disease (SCD) (NCT 01565616) using a reduced toxicity preparative regimen of busulfan (13.2 mg/kg), fl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ecbe8bc4deebd05ed154e8d9ae505ed
https://doi.org/10.1002/ajh.25401
https://doi.org/10.1002/ajh.25401
Autor:
Anita Niedziela-Majka, Haolun Jin, Nikolai Novikov, Nathan Osman, Ernesto Cuadra-Foy, Bluma G. Brenner, Lazerwith Scott E, Kirsten L. White, Federico Campigotto, Morganelli Philip Anthony, Manuel Tsiang, Devleena Shivakumar
Publikováno v:
Antimicrobial Agents and Chemotherapy
The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long dissociation half-life (t1/2) from wild-type IN-DNA complexes: BIC 163 h > dolutegravir (DTG) 96 h > raltegravir (RAL) 10 h > elvitegravir (EVG) 3.3 h. In cells, BI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c57ce3c14873aeaa1aafc412318bd473
https://doi.org/10.1128/aac.02406-20
https://doi.org/10.1128/aac.02406-20